Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 68

1.

Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial.

Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, Tsujikawa T, Fujiyama Y, Mitsuyama K, Sata M, Yamada M, Iwaoka Y, Kanke K, Hiraishi H, Hirayama K, Arai H, Yoshii S, Uchijima M, Nagata T, Koide Y.

Clin Gastroenterol Hepatol. 2006 Dec;4(12):1502-6. Epub 2006 Nov 13.

PMID:
17101300
[PubMed - indexed for MEDLINE]
2.

Curcumin for maintenance of remission in ulcerative colitis.

Kumar S, Ahuja V, Sankar MJ, Kumar A, Moss AC.

Cochrane Database Syst Rev. 2012 Oct 17;10:CD008424. doi: 10.1002/14651858.CD008424.pub2. Review.

PMID:
23076948
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

Feagan BG, Macdonald JK.

Cochrane Database Syst Rev. 2012 Oct 17;10:CD000544. doi: 10.1002/14651858.CD000544.pub3. Review.

PMID:
23076890
[PubMed - indexed for MEDLINE]
4.

A review of infliximab use in ulcerative colitis.

Wilhelm SM, McKenney KA, Rivait KN, Kale-Pradhan PB.

Clin Ther. 2008 Feb;30(2):223-30. doi: 10.1016/j.clinthera.2008.02.014. Review.

PMID:
18343261
[PubMed - indexed for MEDLINE]
5.

A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis.

Nikfar S, Rahimi R, Rezaie A, Abdollahi M.

Dig Dis Sci. 2009 Jun;54(6):1157-70. doi: 10.1007/s10620-008-0481-x. Epub 2008 Sep 4. Review.

PMID:
18770034
[PubMed - indexed for MEDLINE]
6.

Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications.

Schroeder KW.

Scand J Gastroenterol Suppl. 2002;(236):42-7. Review.

PMID:
12408503
[PubMed - indexed for MEDLINE]
7.

Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention.

Sandborn WJ.

Rev Gastroenterol Disord. 2006 Spring;6(2):97-105. Review.

PMID:
16699478
[PubMed - indexed for MEDLINE]
8.

Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis.

Loftus EV Jr, Kane SV, Bjorkman D.

Aliment Pharmacol Ther. 2004 Jan 15;19(2):179-89. Review.

PMID:
14723609
[PubMed - indexed for MEDLINE]
Free Article
9.

The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review.

Kane SV, Bjorkman DJ.

Rev Gastroenterol Disord. 2003 Fall;3(4):210-8. Review.

PMID:
14668693
[PubMed - indexed for MEDLINE]
10.

Comparison of mesalazine and balsalazide in induction and maintenance of remission in patients with ulcerative colitis: a meta-analysis.

Rahimi R, Nikfar S, Rezaie A, Abdollahi M.

Dig Dis Sci. 2009 Apr;54(4):712-21. doi: 10.1007/s10620-008-0428-2. Epub 2008 Aug 6. Review.

PMID:
18683049
[PubMed - indexed for MEDLINE]
11.

Extended-release mesalamine granules for ulcerative colitis.

Love BL, Miller AD.

Ann Pharmacother. 2012 Nov;46(11):1529-36. doi: 10.1345/aph.1R171. Epub 2012 Oct 31. Review.

PMID:
23115226
[PubMed - indexed for MEDLINE]
12.

Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in Ulcerative Colitis: systematic review and meta-analysis.

Ford AC, Khan KJ, Achkar JP, Moayyedi P.

Am J Gastroenterol. 2012 Feb;107(2):167-76; author reply 177. doi: 10.1038/ajg.2011.410. Epub 2011 Nov 22. Review.

PMID:
22108446
[PubMed - indexed for MEDLINE]
13.

Duration of treatment with 5-aminosalicylic acid compounds.

Moshkovska T, Mayberry JF.

World J Gastroenterol. 2007 Aug 28;13(32):4310-5. Review.

PMID:
17708602
[PubMed - indexed for MEDLINE]
Free Article
14.

Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis.

Hanauer SB.

Aliment Pharmacol Ther. 2006 Oct;24 Suppl 3:37-40. Review.

PMID:
16961743
[PubMed - indexed for MEDLINE]
15.

Chemistry, pharmacology, pharmacokinetics, and clinical applications of mesalamine for the treatment of inflammatory bowel disease.

Small RE, Schraa CC.

Pharmacotherapy. 1994 Jul-Aug;14(4):385-98. Review.

PMID:
7937276
[PubMed - indexed for MEDLINE]
16.

Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis.

Ford AC, Khan KJ, Sandborn WJ, Kane SV, Moayyedi P.

Am J Gastroenterol. 2011 Dec;106(12):2070-7; quiz 2078. doi: 10.1038/ajg.2011.296. Epub 2011 Sep 6. Review.

PMID:
21894226
[PubMed - indexed for MEDLINE]
17.

Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: a systematic review and meta-analysis.

Feagan BG, MacDonald JK.

Inflamm Bowel Dis. 2012 Sep;18(9):1785-94. doi: 10.1002/ibd.23024. Epub 2012 May 29. Review.

PMID:
22644954
[PubMed - indexed for MEDLINE]
18.

Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares.

Higgins PD, Rubin DT, Kaulback K, Schoenfield PS, Kane SV.

Aliment Pharmacol Ther. 2009 Feb 1;29(3):247-57. doi: 10.1111/j.1365-2036.2008.03865.x. Epub 2008 Oct 7. Review.

PMID:
18945258
[PubMed - indexed for MEDLINE]
19.

Multi-matrix system mesalamine: to use or not to use.

Kale-Pradhan PB, Pradhan RS, Wilhelm SM.

Ann Pharmacother. 2008 Feb;42(2):265-9. doi: 10.1345/aph.1K469. Epub 2008 Jan 8. Review.

PMID:
18182473
[PubMed - indexed for MEDLINE]
20.

Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis.

Ford AC, Achkar JP, Khan KJ, Kane SV, Talley NJ, Marshall JK, Moayyedi P.

Am J Gastroenterol. 2011 Apr;106(4):601-16. doi: 10.1038/ajg.2011.67. Epub 2011 Mar 15. Review.

PMID:
21407188
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk